logo

Tyme Technologies, Inc. (TYME)



Trade TYME now with
  Date
  Headline
7/5/2019 8:05:36 AM TYME Presents Updated Data At ESMO GI 2019 From TYME-88-Panc Phase II Study
4/1/2019 8:14:16 AM Tyme Technologies Reports Dismissal Of Class Action Lawsuit
3/29/2019 8:08:56 AM Tyme Technologies Reports Pricing Of $12 Mln Registered Offering
2/11/2019 7:47:31 AM Tyme Technologies Q3 Loss Per Share $0.08 Vs Loss $0.06 Last Year
1/4/2019 8:07:11 AM Tyme Reports Presentation Of SM-88 Data At 2019 ASCO Genitourinary Cancers Symposium
10/15/2018 8:04:17 AM Tyme Appoints Michele Korfin As Chief Commercial Officer
9/18/2018 8:06:06 AM Tyme Technologies Names Douglas Michels To Board; Appoints James Biehl As Chief Legal Officer
5/30/2018 7:38:02 AM Tyme Appoints Don DeGolyer To Board Of Directors
4/9/2018 7:18:13 AM Tyme Provides Clinical And Corporate Update For 2018
3/27/2018 8:12:12 AM Tyme Announces First Site Open For Its Phase II Trial With SM-88 In Pancreatic Cancer
3/14/2018 8:07:59 AM Tyme Technologies: FDA Accepts IND Application To Initiate Phase II Clinical Trial For SM-88 In Pancreatic Cancer
3/8/2018 8:11:34 AM Tyme Technologies Reports Closing Of Public Offering Of Common Stock
3/1/2018 10:00:55 PM Tyme Technologies Prices Public Offering Of 9 Mln Shares At $2.25/shr
2/21/2018 9:01:07 AM Tyme Technologies Appoints Tommy Thompson To Board
  
 
>